Premier African Minerals Share Discussion Threads

[activeservo] 09/10/2017 08:26

Many reasons.

To me they fall into the same category of AIM share. Heavily discounted, massive "potential".

Both companies in good financial position.

PREM seems to be the next UKOG in my eyes, consistent with Jung's "best AIM share" post earlier. So I assume others think the same.

The BB shows some of the UKOG posters came over here recently (including you and I....!) showing it's on the same radar as those invested in UKOG.

I noticed when UKOG topped out back in end of July those selling jumped in here...

Also, both companies are associated with DL who has a massive following.

Herd mentality.

[vitec] 09/10/2017 08:12

active, why would people be selling out of UKOG and find their way to PREM?

[activeservo] 09/10/2017 08:09

I think this should have a slight boost as people start selling out of UKOG this week.

[vitec] 09/10/2017 08:07

Mike, I agree with everything xulu has written. Every man and his dog probably understands the assets and their potential worth. What the market wants to see is this potential translated into revenue and profits. Until the evidence solidifies at the very least the share price is going to stay quagmired.

As far as throwing the kitchen sink at PREM. I have thrown the entire bathroom and kitchen suite at it and expect my reward.

[mike_f] 09/10/2017 07:44

Courtesy of Zulu on LSE:Any day now: Zulu Assays and Resource Upgrade: This will not only increase the Main Zone but add the SE Zone which is at least the same size as the Main Zone. I.e It's going to double the resource when properly drilled. It was also clearly high-grade as per the pictures. GR/DL have also implied this. Any day now: Crusher installed. 8 weeks from 31st July. XRT was limited to 55% - it will allow increase to 100%. By end of month: Additional Stope faces open at RHA underground to allow more mining of the higher grade ore. By end of month: RHA Open Pit assessment: This will be an upgraded resource model of the Open Pit detailed in November. As per RNS, operations will exceed previous guidance. Early November: Zulu PEA: This will establish an introductory economic analysis of the Zulu deposit - establish a basic mine plan and initial NPV for the project. Other AIM miners are 10-20% of their NPV with PEA only. By end of quarter: Zulu JV/Sale: Buyers were already lined up in Summer. They're waiting in the wings. We re-commence discussions after PEA. Latter part of Q4: RHA profitable business. Underground comfortably 6000 tonnes per month vs 4500 breakeven required. Open Pit to be added. Doubling profits at least! By end of quarter: Circum update. Culmination of build up to the liquidity event. We now own 5.2% - our NPV upto $109m.

[cambradjones] 09/10/2017 07:32

I wish i had a kitchen sink to chuck at it !

[markth126] 08/10/2017 22:16

Hope your right Jung as I have thrown kitchen sink at it after making a chunk on TRIN

[jungmana] 08/10/2017 21:47

Over last one week I have been convinced that there is no better company for a massive return than PREM on aim. Come early in the new year many will wish they had thrown the kitchen sink at this. Good luck all. The next 3 months will not be boring here.

[mike_f] 08/10/2017 20:49

Cool Druid, FO

[cool druid] 08/10/2017 12:51

[...]

Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS)
By Alliance | Fri, 6th October 2017 - 14:19

LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company.
The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin.
Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo.
The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%.
Merrill Lynch had a holding that was below the notable threshold prior to the purchase.
Motif Bio shares were up 6% on Friday at 46.11 pence.
By Joshua Warner; [e-mail]; @JoshAlliance

Read more:

A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure.
Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment

[donald tramp] 07/10/2017 19:29

I think that would make me a squillionaire if we hit 2p..... Or should I say when we hit 2p.

[mike_f] 07/10/2017 19:10

cambrad, I'm well underwater on a few of my purchases as well. I personally feel a JV will be forthcoming pre Christmas and think that is where we will see the greatest appreciation in price. On JV I'd be extremely upset if we didn't hit an absolute minimum of 2p.

[turbotrader2] 07/10/2017 18:28

I do not see 1p as a problem with great assays as that will lead to an even stronger PEA

[cambradjones] 07/10/2017 18:03

MikeI need a 200 % rise just to get back to my but in price about 6 weeks ago.Sickening really.

[mike_f] 07/10/2017 16:50

I agree DT, I'm just trying to be more conservative after recent events and additional shares in issue to churn along the way. Even 1p is still a 200% increase from current levels! Not bad for a few months hold...

[goodgrief] 07/10/2017 13:42

KoP, at least none of the assets are diamond mines or the Mugabes would be filling their pockets...

[merill] 07/10/2017 12:36

2 us biggies are buying Motif (MTFB). Both bought 5% each in 2 days.
Merrill Lynch


Good news hit the wires this morning from Motif Bio (LSE: MTFB), a clinical-stage biopharmaceutical company aiming to develop novel antibiotics. The market likes it and the shares are around 36% higher as I write.
The excitement surrounds details of a positive topline result from a global Phase 3 clinical trial called REVIVE-2, which is focused on the firm’s investigational drug candidate iclaprim for patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).


A new drug is born
Chief executive Graham Lumsden tells us that today’s positive results mean the company has completed the two required Phase 3 trials in ABSSSI necessary to submit a new drug application to the US Food and Drug Administration (FDA), which Motif Bio plans to do by the end of the first quarter of 2018.
According to medical experts, ABSSSI is a serious infection and every year around 3.6m people in the US are hospitalised with it for several days. The problem with existing treatments is that they tend to be toxic to the kidneys and that’s bad because around 26% of those suffering with ABSSSI also have kidney disease. Happily, during the trial, kidney toxicity was not observed with iclaprim.
The hope now is that Iclaprim may prove to be “an important option for the growing population of patients with ABSSSI and kidney disease who need a safe and effective antibiotic targeting Gram-positive bacteria, including MRSA.” Meanwhile, from an investing point of view, the outcome of the trial means that Iclaprim now has value, which Motif Bio may be able to commercialise down the road.


Motif Bio presents drug trial data
6th October 2017 08:16 | Motif Bio Plc Ord 1p
Motif Bio has presented new pre-clinical data regarding its investigational drug candidate iclaprim to the IDWeek 2017 conference in San Diego.

"The data presented today underscore the potential utility of iclaprim in a range of patient populations with suspected MRSA infections, including cystic fibrosis patients with Staphylococcus aureus lung infections," Motif Bio chief medical officer David Huang said.


At 8:16am: (LON:MTFB) Motif Bio Plc Ord 1p share price was +0.25p at 43.75p





Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS)
By Alliance | Fri, 6th October 2017 - 14:19

LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company.
The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin.
Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo.
The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%.
Merrill Lynch had a holding that was below the notable threshold prior to the purchase.
Motif Bio shares were up 6% on Friday at 46.11 pence.
By Joshua Warner; [e-mail]; @JoshAlliance
Copyright 2017 Alliance News Limited. All Rights Reserved.


Motif Bio PLC Holding(s) in Company
05/10/2017 9:57am
UK Regulatory (RNS & others)


TIDMMTFB
RNS Number : 8030S
Motif Bio PLC
05 October 2017

NOTIFICATION OF MAJOR HOLDINGS
-----------------------------------------------------------------------------------------------------

1a. Identity of the issuer MOTIF BIO PLC
or the underlying issuer
of existing shares to which
-----------------------------------------------------------------------------------------------------
% of voting % of voting Total of Total number
rights attached rights through both in % of voting
to shares financial (8.A + 8.B) rights of
(total of instruments issuer(vii)
8. A) (total of
8.B 1 + 8.B
2)
---------------------- -------------------------- ---------------- ---------------- -------------
Resulting
situation
on the date
on which
threshold
was crossed
or reached 5.03% 5.03% 13,257,448





3. Details of person subject to the notification obligation(iv)
Name SAND GROVE CAPITAL MANAGEMENT
LLP
City and country of registered LONDON, UK
office (if applicable)
4. Full name of shareholder(s) (if different from 3.)(v)
-----------------------------------------------------------------------------------------------------
Name SAND GROVE OPPORTUNITIES
MASTER FUND LTD

[donald tramp] 07/10/2017 10:48

I don't think we would need all of those to hit 1p+ Mike, further good assays and PEA should move us to that level. I think RHA profitable at predicted levels is worth about 1.5p in it's own right easily.

[mike_f] 07/10/2017 10:34

Ok F3rdinand, then why was the share price at .4p when it should have been .8p+ etc, it’s because financing has been a bit of a disaster of late and that ultimately comes down to GR! If PB was done in the first instance when the share price was .7p+ I don’t believe we would currently be at these levels.

Having said that, I believe that is now in the past, we don’t have YA or Darwin (for much longer) involved with lots of warrants etc, as soon as the current placing shares are all absorbed (personally I think we are nearly there) then the price will start to move up in anticipation of news.

I still think we could hit 1p+ before Christmas on great assays, a very positive PEA and RHA hitting full production. If a JV occurs before Santa comes I see a lot more than 1p if everything else has fallen into place nicely! Very exciting quarter ahead with the financing issues now in the past. GLA

[turbotrader2] 07/10/2017 09:46

I think the assays will come as early as Monday or Tuesday hopefully Tuesday when the placees have sold for a 5% profit

[andrewsr] 07/10/2017 09:13

The 'delay' in getting the assays back must affect the timing of the PEA, so perhaps a bit longer than GR anticipated in September.

[f3rdinand] 07/10/2017 07:59

The share price isn't 0.3p because of lack of confidence in GR; it's because there has been a placing of nearly a billion shares that Darwin have been offloading aggressively! These shares are being lapped up by PI's so it's unfair to summise investors have lost confidence! When they clear (early next week at a guess) I would expect a large rise as the market cap in no way reflects the assets and potential that PREM has! IMHO

[mike_f] 06/10/2017 21:45

Because confidence in GR was knocked markth126, as soon as the positive news starts to flow the share price will start to reflect true value again IMO.